Diabetic cardiomyopathy, Transthyretin amyloidosis, Transthyretin Amyloid Cardiomyopathy
IONSIonis PharmaceuticalsCatalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for Eplontersen (AKCEA-TTR-LRx) in Diabetic cardiomyopathy, Transthyretin amyloidosis, Transthyretin Amyloid Cardiomyopathy. The expected timing is based on the latest available company guidance and may change.
CARDIO-TTRansform. Partnered with AstraZeneca. Phase 3 full enrollment 7/31/2023, data in 2026. 01/11/26:- CARDIO-TTRansform Ph3 ATTR-CM results expected in H2 2026; sNDA submission planned afterward. 07/08/26:- CARDIO-TTRansform missed primary endpoint; monotherapy subgroup nominal benefit. Full dataset to be presented at ESC Aug 2026. 08/20/26:- CARDIO-TTRansform Phase 3 analyses to present at ESC 2026 Aug 28.
Verification
Confirm timing and program details against the company announcement or filing.